Drugs / Omr-IgG-am
Omr-IgG-am
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00068055 | Sep 2003 → Dec 2006 | Flaviviridae infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00069316 | Sep 2003 → Jun 2007 | West Nile fever | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00468273 | Nov 2006 → May 2009 | immunodeficiency disease | FFF Enterprises | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OMR-IGG-AM | “Omr-IgG-am™ 5% is provided in 100 ml bottles (5.0 grams) as a sterile solution containing 5% protein, 10% maltose and water for injection.” NCT00068055 ↗3“Omr-IgG-am™ 5% is provided in 100 ml bottles (5.0 grams) as a sterile solution containing 5% protein, 10% maltose and water for injection.” NCT00068055 ↗ |
| Known as | IGIV | “Immune Globulin Intravenous (Human) [IGIV], 5% Solution Omr-IgG-am™ in patients with primary immunodeficiency diseases.” NCT00468273 ↗ |
| Known as | Omr-lgG-am | “Drug: Omr-lgG-am” NCT00068055 ↗ |
| Modality | Protein / enzyme biologic | “an intravenous immunoglobulin (IVIg) containing antibodies specific for West Nile virus (WNV)” NCT00068055 ↗ |
| Route | Intravenous | “Patients will receive a single intravenous dose of study medication or one of two placebos.” NCT00068055 ↗ |